Abelmoschus manihot Polysaccharides Target the AMPK/Nrf2/HO-1 Signalling Pathway to Inhibit Macrophage M1 Polarisation and Hepatic Stellate Cell Activation Improving Liver Fibrosis in Mice.

Authors

Shixing Li, Zukuan Chang, Jinzhan Liu, Huilin Lu

Published in

Journal of cellular and molecular medicine. Volume 30. Issue 14. Pages e71294.

Abstract

Liver fibrosis (LF) is a critical pathological stage in the progression from chronic liver disease to cirrhosis. While Abelmoschus manihot polysaccharides (AMP) demonstrate hepatoprotective potential, the underlying anti-fibrotic mechanisms remain incompletely understood. A carbon tetrachloride-induced LF mouse model was established followed by AMP intervention. Comprehensive assessments included ELISA measurement of serum biochemical indicators (ALT, AST, ALP, TBA, TBil), fibrosis markers (HA, PC III, LN, Hyp) and inflammatory cytokines (IL-1β, TNF-α, IL-6, IL-10). Liver tissue pathological changes were evaluated through haematoxylin-eosin (HE), Masson and Sirius Red staining. In vitro experiments utilised TGF-β1-stimulated JS-1 and LPS/IFN-γ-induced M1-type RAW264.7 macrophages. Experimental techniques encompassed MTT assay, immunofluorescence, qPCR, Western blot and flow cytometry to analyse cellular markers and signalling pathways. The study specifically investigated AMP's regulatory effects on macrophage polarisation and hepatic stellate cell activation, using the AMPK inhibitor (Compound C) to explore potential mechanistic pathways. AMP treatment effectively mitigated CCl₄-induced liver injury by reducing serum markers (ALT, AST, HA, PC III, Hyp) and pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) while increasing anti-inflammatory IL-10. Mechanistically, AMP regulated macrophage polarisation (inhibiting M1 markers iNOS/CD80/CD86 while promoting M2 markers CD206/Arg-1) and suppressed fibrogenesis by downregulating α-SMA, Collagen I and TIMP1 while upregulating MMP13. These effects were mediated through activation of the AMPK/Nrf2/HO-1 pathway, ultimately inhibiting HSCs activation and extracellular matrix (ECM) accumulation. The AMPK inhibitor Compound C attenuates these protective effects. AMP alleviates LF by activating the AMPK/Nrf2/HO-1 pathway, modulating macrophage polarisation and ECM remodelling, demonstrating promising therapeutic potential.

PMID:
42503305
Bibliographic data and abstract were imported from PubMed on 27 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.